GLPG 1690

Drug Profile

GLPG 1690

Alternative Names: GLPG1690

Latest Information Update: 05 Jul 2017

Price : $50

At a glance

  • Originator Galapagos NV
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action ENPP2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis

Most Recent Events

  • 29 Jun 2017 Galapagos completes a phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in Belgium (PO, Tablet and Capsule) (NCT03143712)
  • 20 Jun 2017 GLPG 1690 receives Orphan Drug status for Idiopathic pulmonary fibrosis in USA
  • 02 May 2017 Galapagos completes a phase II trial in Idiopathic pulmonary fibrosis in United Kingdom and Ukraine (PO) (NCT02738801)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top